Shares of Biogen Inc. BIIB slid 1.10% to $142.34 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...
Zacks.com on MSN9h
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's DrugBiogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...
We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Biogen Inc.
Recent health news highlights include a review of the safety of Alzheimer's drug Leqembi, legal charges against a New York ...
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...
Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback